Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: dobashi n. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
[Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Saito T, Usui N, Dobashi N, Maki N, Asai O, Yano S, Kato A, Watanabe H, Katori M, Nagamine M, Ogihara A, Yamazaki H, Kobayashi T, Tajima N, Kuraishi Y. Saito T, et al. Among authors: dobashi n. Rinsho Ketsueki. 1998 Jul;39(7):481-6. Rinsho Ketsueki. 1998. PMID: 9750454 Japanese.
[The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
Usui N, Dobashi N, Asai O, Yano S, Kato A, Osawa H, Uno S, Katori M, Nagamine M, Yahagi Y, Yamaguchi Y, Saito T, Kasama K, Takei Y, Ogihara A, Yamazaki H, Kobayashi T, Tajima N, Ogawa M, Kuraishi Y. Usui N, et al. Among authors: dobashi n. Gan To Kagaku Ryoho. 2000 Jul;27(8):1152-9. Gan To Kagaku Ryoho. 2000. PMID: 10945010 Clinical Trial. Japanese.
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R. Kobayashi Y, et al. Among authors: dobashi n. Int J Hematol. 2009 May;89(4):460-469. doi: 10.1007/s12185-009-0298-1. Epub 2009 Apr 10. Int J Hematol. 2009. PMID: 19360457 Clinical Trial.
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N. Nagai T, et al. Among authors: dobashi n. Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25. Int J Hematol. 2010. PMID: 20577839 Clinical Trial.
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, Kobayashi Y, Sakura T, Yahagi Y, Shigeno K, Ohwada C, Miyazaki Y, Ohtake S, Miyawaki S, Naoe T, Ohnishi K; Japan Adult Leukemia Study Group. Usui N, et al. Among authors: dobashi n. Cancer Sci. 2011 Jul;102(7):1358-65. doi: 10.1111/j.1349-7006.2011.01957.x. Epub 2011 May 18. Cancer Sci. 2011. PMID: 21585619 Free article. Clinical Trial.
The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.
Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda T, Miyamura K, Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi J, Takahashi M, Dobashi N, Kiyoi H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: dobashi n. Cancer. 2013 Sep 15;119(18):3326-33. doi: 10.1002/cncr.28212. Epub 2013 Jun 24. Cancer. 2013. PMID: 23798329 Free article. Clinical Trial.
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.
Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. Shinagawa K, et al. Among authors: dobashi n. J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245439 Clinical Trial.
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T. Fujisawa S, et al. Among authors: dobashi n. Am J Hematol. 2017 Apr;92(4):367-374. doi: 10.1002/ajh.24653. Epub 2017 Feb 21. Am J Hematol. 2017. PMID: 28103625 Free article. Clinical Trial.
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. Hatta Y, et al. Among authors: dobashi n. Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24. Ann Hematol. 2018. PMID: 29694642 Free PMC article.
97 results